Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
Identifieur interne : 003B56 ( Main/Exploration ); précédent : 003B55; suivant : 003B57Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
Auteurs : Mary C. Hu [États-Unis] ; Taff Jones [Canada] ; Richard T. Kenney [États-Unis] ; Dale L. Barnard [États-Unis] ; David S. Burt [Canada] ; George H. Lowell [Canada]Source :
- Vaccine [ 0264-410X ] ; 2007.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Animaux, Anticorps antiviraux (biosynthèse), Association médicamenteuse, Cysteine endopeptidases (administration et posologie), Cysteine endopeptidases (immunologie), Cytokines (biosynthèse), Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (immunologie), Immunisation, Lipopolysaccharides (administration et posologie), Lipopolysaccharides (immunologie), Poumon (immunologie), Protéines de l'enveloppe virale (immunologie), Souris, Souris de lignée BALB C, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Cysteine endopeptidases, Lipopolysaccharides, Vaccins antiviraux, Vaccins synthétiques.
- biosynthèse : Anticorps antiviraux, Cytokines.
- immunologie : Cysteine endopeptidases, Glycoprotéines membranaires, Lipopolysaccharides, Poumon, Protéines de l'enveloppe virale, Vaccins antiviraux, Vaccins synthétiques, Virus du SRAS.
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Antibodies, Viral (biosynthesis), Cysteine Endopeptidases (administration & dosage), Cysteine Endopeptidases (immunology), Cytokines (biosynthesis), Drug Combinations, Female, Immunization, Intranasal administration, Lipopolysaccharides (administration & dosage), Lipopolysaccharides (immunology), Lung (immunology), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Mouse, Neutralizing antibody, Recombinant protein, SARS Virus (immunology), Serum protein, Spike Glycoprotein, Coronavirus, Vaccine, Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Cysteine Endopeptidases, Lipopolysaccharides, Vaccines, Synthetic, Viral Vaccines.
- chemical , biosynthesis : Antibodies, Viral, Cytokines.
- chemical , immunology : Cysteine Endopeptidases, Lipopolysaccharides, Membrane Glycoproteins, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines.
- immunology : Lung, SARS Virus.
- Administration, Intranasal, Animals, Drug Combinations, Female, Immunization, Mice, Mice, Inbred BALB C, Spike Glycoprotein, Coronavirus.
Abstract
The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000356
- to stream PascalFrancis, to step Curation: 000633
- to stream PascalFrancis, to step Checkpoint: 000367
- to stream Main, to step Merge: 003D14
- to stream Pmc, to step Corpus: 001531
- to stream Pmc, to step Curation: 001531
- to stream Pmc, to step Checkpoint: 000F40
- to stream PubMed, to step Corpus: 001D64
- to stream PubMed, to step Curation: 001D64
- to stream PubMed, to step Checkpoint: 001D67
- to stream Ncbi, to step Merge: 001A20
- to stream Ncbi, to step Curation: 001A20
- to stream Ncbi, to step Checkpoint: 001A20
- to stream Main, to step Merge: 003799
- to stream Main, to step Curation: 003B56
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice</title><author><name sortKey="Hu, Mary C" sort="Hu, Mary C" uniqKey="Hu M" first="Mary C." last="Hu">Mary C. Hu</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway</s1><s2>Bothell, WA 98011</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Jones, Taff" sort="Jones, Taff" uniqKey="Jones T" first="Taff" last="Jones">Taff Jones</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1><s2>Montreal, Quebec H7V 3S8</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec H7V 3S8</wicri:noRegion></affiliation></author><author><name sortKey="Kenney, Richard T" sort="Kenney, Richard T" uniqKey="Kenney R" first="Richard T." last="Kenney">Richard T. Kenney</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>GlaxoSmithKline Biologicals North America of Maryland, 6996 Columbia Gateway Drive</s1><s2>Columbia, MA 21046</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L." last="Barnard">Dale L. Barnard</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Institute for Antiviral Research, Department of ADVS, Utah State University</s1><s2>Logan, UT 84322</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Burt, David S" sort="Burt, David S" uniqKey="Burt D" first="David S." last="Burt">David S. Burt</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1><s2>Montreal, Quebec H7V 3S8</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec H7V 3S8</wicri:noRegion></affiliation></author><author><name sortKey="Lowell, George H" sort="Lowell, George H" uniqKey="Lowell G" first="George H." last="Lowell">George H. Lowell</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1><s2>Montreal, Quebec H7V 3S8</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec H7V 3S8</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0388604</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0388604 INIST</idno><idno type="RBID">Pascal:07-0388604</idno><idno type="wicri:Area/PascalFrancis/Corpus">000356</idno><idno type="wicri:Area/PascalFrancis/Curation">000633</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000367</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000367</idno><idno type="wicri:doubleKey">0264-410X:2007:Hu M:intranasal:protollin:formulated</idno><idno type="wicri:Area/Main/Merge">003D14</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115497</idno><idno type="RBID">PMC:7115497</idno><idno type="wicri:Area/Pmc/Corpus">001531</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001531</idno><idno type="wicri:Area/Pmc/Curation">001531</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001531</idno><idno type="wicri:Area/Pmc/Checkpoint">000F40</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000F40</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17640780</idno><idno type="wicri:Area/PubMed/Corpus">001D64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D64</idno><idno type="wicri:Area/PubMed/Curation">001D64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D64</idno><idno type="wicri:Area/PubMed/Checkpoint">001D67</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D67</idno><idno type="wicri:Area/Ncbi/Merge">001A20</idno><idno type="wicri:Area/Ncbi/Curation">001A20</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A20</idno><idno type="wicri:doubleKey">0264-410X:2007:Hu M:intranasal:protollin:formulated</idno><idno type="wicri:Area/Main/Merge">003799</idno><idno type="wicri:Area/Main/Curation">003B56</idno><idno type="wicri:Area/Main/Exploration">003B56</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice</title><author><name sortKey="Hu, Mary C" sort="Hu, Mary C" uniqKey="Hu M" first="Mary C." last="Hu">Mary C. Hu</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway</s1><s2>Bothell, WA 98011</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Jones, Taff" sort="Jones, Taff" uniqKey="Jones T" first="Taff" last="Jones">Taff Jones</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1><s2>Montreal, Quebec H7V 3S8</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec H7V 3S8</wicri:noRegion></affiliation></author><author><name sortKey="Kenney, Richard T" sort="Kenney, Richard T" uniqKey="Kenney R" first="Richard T." last="Kenney">Richard T. Kenney</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>GlaxoSmithKline Biologicals North America of Maryland, 6996 Columbia Gateway Drive</s1><s2>Columbia, MA 21046</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L." last="Barnard">Dale L. Barnard</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Institute for Antiviral Research, Department of ADVS, Utah State University</s1><s2>Logan, UT 84322</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Burt, David S" sort="Burt, David S" uniqKey="Burt D" first="David S." last="Burt">David S. Burt</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1><s2>Montreal, Quebec H7V 3S8</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec H7V 3S8</wicri:noRegion></affiliation></author><author><name sortKey="Lowell, George H" sort="Lowell, George H" uniqKey="Lowell G" first="George H." last="Lowell">George H. Lowell</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1><s2>Montreal, Quebec H7V 3S8</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec H7V 3S8</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Viral (biosynthesis)</term><term>Cysteine Endopeptidases (administration & dosage)</term><term>Cysteine Endopeptidases (immunology)</term><term>Cytokines (biosynthesis)</term><term>Drug Combinations</term><term>Female</term><term>Immunization</term><term>Intranasal administration</term><term>Lipopolysaccharides (administration & dosage)</term><term>Lipopolysaccharides (immunology)</term><term>Lung (immunology)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mouse</term><term>Neutralizing antibody</term><term>Recombinant protein</term><term>SARS Virus (immunology)</term><term>Serum protein</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccine</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Anticorps antiviraux (biosynthèse)</term><term>Association médicamenteuse</term><term>Cysteine endopeptidases (administration et posologie)</term><term>Cysteine endopeptidases (immunologie)</term><term>Cytokines (biosynthèse)</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (immunologie)</term><term>Immunisation</term><term>Lipopolysaccharides (administration et posologie)</term><term>Lipopolysaccharides (immunologie)</term><term>Poumon (immunologie)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins synthétiques (administration et posologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cysteine Endopeptidases</term><term>Lipopolysaccharides</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term><term>Cytokines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cysteine Endopeptidases</term><term>Lipopolysaccharides</term><term>Membrane Glycoproteins</term><term>Vaccines, Synthetic</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cysteine endopeptidases</term><term>Lipopolysaccharides</term><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cysteine endopeptidases</term><term>Glycoprotéines membranaires</term><term>Lipopolysaccharides</term><term>Poumon</term><term>Protéines de l'enveloppe virale</term><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung</term><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Drug Combinations</term><term>Female</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Association médicamenteuse</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Immunisation</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Voie intranasale</term><term>Protéine recombinante</term><term>Protéine sérique</term><term>Anticorps neutralisant</term><term>Vaccin</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Massachusetts</li><li>Utah</li><li>Washington (État)</li></region></list><tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Hu, Mary C" sort="Hu, Mary C" uniqKey="Hu M" first="Mary C." last="Hu">Mary C. Hu</name></region><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L." last="Barnard">Dale L. Barnard</name><name sortKey="Kenney, Richard T" sort="Kenney, Richard T" uniqKey="Kenney R" first="Richard T." last="Kenney">Richard T. Kenney</name></country><country name="Canada"><noRegion><name sortKey="Jones, Taff" sort="Jones, Taff" uniqKey="Jones T" first="Taff" last="Jones">Taff Jones</name></noRegion><name sortKey="Burt, David S" sort="Burt, David S" uniqKey="Burt D" first="David S." last="Burt">David S. Burt</name><name sortKey="Lowell, George H" sort="Lowell, George H" uniqKey="Lowell G" first="George H." last="Lowell">George H. Lowell</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:07-0388604
|texte= Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
}}
| This area was generated with Dilib version V0.6.33. |  |